{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:15:13Z","timestamp":1788999313026,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019703","name":"Lunit Inc","doi-asserted-by":"publisher","award":["LS No. 023"],"award-info":[{"award-number":["LS No. 023"]}],"id":[{"id":"10.13039\/100019703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.108021","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:04:51Z","timestamp":1783353891000},"page":"108021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-0642","authenticated-orcid":false,"given":"H.-D.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-0644","authenticated-orcid":false,"given":"T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4298-0903","authenticated-orcid":false,"given":"S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-Y.","family":"Ock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5774-361X","authenticated-orcid":false,"given":"G.","family":"Carloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-1263","authenticated-orcid":false,"given":"M.-H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10494","key":"10.1016\/j.esmoop.2026.108021_bib1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.esmoop.2026.108021_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108021_bib3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108021_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108021_bib5","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108021_bib6","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108021_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"10389","key":"10.1016\/j.esmoop.2026.108021_bib8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108021_bib9","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108021_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108021_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10120-025-01618-6","article-title":"Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108021_bib12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","volume":"31","author":"Shitara","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108021_bib13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s10120-024-01509-2","article-title":"Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair","volume":"27","author":"Park","year":"2024","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108021_bib14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10120-024-01500-x","article-title":"Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy","volume":"27","author":"Kim","year":"2024","journal-title":"Gastric Cancer"},{"issue":"17","key":"10.1016\/j.esmoop.2026.108021_bib15","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.21.02010","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108021_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008339","article-title":"Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types","volume":"12","author":"Shen","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.esmoop.2026.108021_bib17","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1158\/1078-0432.CCR-24-1265","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a potential biomarker for immune checkpoint inhibitors in patients with biliary tract cancer","volume":"30","author":"Bang","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108021_bib18","article-title":"Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108021_bib19","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108021_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10120-024-01566-7","article-title":"Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.esmoop.2026.108021_bib21","article-title":"An image is worth 16x16 words: transformers for image recognition at scale","author":"Dosovitskiy","year":"2021","journal-title":"arXiv"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108021_bib22","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108021_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108021_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12964-023-01406-8","article-title":"Claudin-18.2 mediated interaction of gastric cancer cells and cancer-associated fibroblasts drives tumor progression","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108021_bib25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.5230\/jgc.2025.25.e47","article-title":"Correlation and overlap between claudin 18.2 and FGFR2b overexpression: a tissue microarray study with 1,538 gastric carcinomas","volume":"25","author":"Ahn","year":"2025","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.esmoop.2026.108021_bib26","article-title":"Prognostic indicators of preoperative fluorouracil, leucovorin, oxaliplatin, and docetaxel efficacy in locally advanced gastroesophageal and gastric cancer: integrating biomarker analysis and clinicopathological factors","volume":"9","author":"Jubashi","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108021_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012683","article-title":"Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy","volume":"13","author":"Lim","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108021_bib28","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41591-025-03898-y","article-title":"Evolution of claudin18.2 therapies in gastroesophageal cancers","volume":"31","author":"Klempner","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108021_bib29","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","article-title":"The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial","volume":"31","author":"Ruan","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108021_bib30","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926019630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926019630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:51:22Z","timestamp":1785963082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926019630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926019630"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108021","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108021"}}